These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15180891)

  • 1. Targeting B cells for the treatment of rheumatoid arthritis.
    Oligino TJ; Dalrymple SA
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S7-11. PubMed ID: 15180891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus.
    Henneken M; Dörner T; Burmester GR; Berek C
    Arthritis Res Ther; 2005; 7(5):R1001-13. PubMed ID: 16207316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
    Hainsworth JD
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
    Di W; Chang Y; Wu YJ; Wei W
    Sheng Li Ke Xue Jin Zhan; 2011 Jun; 42(3):175-80. PubMed ID: 21932514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives.
    Nakken B; Munthe LA; Konttinen YT; Sandberg AK; Szekanecz Z; Alex P; Szodoray P
    Autoimmun Rev; 2011 Nov; 11(1):28-34. PubMed ID: 21777703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
    Edwards JC; Leandro MJ; Cambridge G
    Curr Dir Autoimmun; 2005; 8():175-92. PubMed ID: 15564721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases.
    Mariette X
    Joint Bone Spine; 2004 Sep; 71(5):357-60. PubMed ID: 15474382
    [No Abstract]   [Full Text] [Related]  

  • 13. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.
    Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 May; 66(5):700-3. PubMed ID: 17040963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis.
    Nanki T; Shimaoka T; Hayashida K; Taniguchi K; Yonehara S; Miyasaka N
    Arthritis Rheum; 2005 Oct; 52(10):3004-14. PubMed ID: 16200580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD20 antibody for treatment of rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():544-8. PubMed ID: 15799415
    [No Abstract]   [Full Text] [Related]  

  • 17. [Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution].
    Sany J
    C R Biol; 2006 Apr; 329(4):228-40. PubMed ID: 16644493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.
    Hu C; Xiong J; Zhang L; Huang B; Zhang Q; Li Q; Yang M; Wu Y; Wu Q; Shen Q; Gao Q; Zhang K; Sun Z; Liu J; Jin Y; Tan J
    Cell Mol Immunol; 2004 Aug; 1(4):280-94. PubMed ID: 16225771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline.
    Ding C; Jones G
    Curr Opin Investig Drugs; 2006 May; 7(5):464-72. PubMed ID: 16729724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.